HC Wainwright Has Pessimistic Outlook of TVTX Q2 Earnings

Travere Therapeutics, Inc. (NASDAQ:TVTX - Free Report) - Equities research analysts at HC Wainwright cut their Q2 2025 EPS estimates for Travere Therapeutics in a note issued to investors on Tuesday, July 1st. HC Wainwright analyst J. Pantginis now anticipates that the company will post earnings per share of ($0.54) for the quarter, down from their previous estimate of ($0.38). HC Wainwright currently has a "Buy" rating and a $30.00 price target on the stock. The consensus estimate for Travere Therapeutics' current full-year earnings is ($1.40) per share. HC Wainwright also issued estimates for Travere Therapeutics' Q3 2025 earnings at ($0.62) EPS, Q4 2025 earnings at ($0.62) EPS, FY2025 earnings at ($2.30) EPS, FY2026 earnings at ($0.86) EPS, FY2027 earnings at ($0.17) EPS, FY2028 earnings at $0.13 EPS and FY2029 earnings at $0.47 EPS.

TVTX has been the topic of several other research reports. Scotiabank restated an "outperform" rating on shares of Travere Therapeutics in a research note on Friday, April 11th. Stifel Nicolaus boosted their target price on shares of Travere Therapeutics from $22.00 to $23.00 and gave the company a "hold" rating in a research note on Friday, May 2nd. Cantor Fitzgerald reiterated an "overweight" rating on shares of Travere Therapeutics in a research report on Wednesday, April 23rd. Canaccord Genuity Group upped their price target on shares of Travere Therapeutics from $45.00 to $47.00 and gave the stock a "buy" rating in a research report on Thursday, April 10th. Finally, Bank of America upped their price target on shares of Travere Therapeutics from $29.00 to $31.00 and gave the stock a "buy" rating in a research report on Tuesday, April 1st. Two equities research analysts have rated the stock with a hold rating and thirteen have given a buy rating to the company's stock. According to MarketBeat, the stock has a consensus rating of "Moderate Buy" and a consensus target price of $32.14.

Travere Therapeutics Stock Performance

Travere Therapeutics stock traded up $0.16 on Thursday, hitting $15.00. The company's stock had a trading volume of 663,493 shares, compared to its average volume of 1,616,530. The firm has a market cap of $1.33 billion, a P/E ratio of -5.34 and a beta of 0.72. The company has a quick ratio of 2.03, a current ratio of 2.05 and a debt-to-equity ratio of 9.46. The company has a fifty day moving average price of $16.72 and a 200-day moving average price of $18.13. Travere Therapeutics has a one year low of $7.72 and a one year high of $25.29.

Travere Therapeutics (NASDAQ:TVTX - Get Free Report) last announced its earnings results on Thursday, May 1st. The company reported ($0.47) earnings per share (EPS) for the quarter, topping analysts' consensus estimates of ($0.55) by $0.08. Travere Therapeutics had a negative net margin of 82.88% and a negative return on equity of 1,179.73%. The business had revenue of $81.73 million for the quarter, compared to analyst estimates of $77.44 million. During the same quarter in the previous year, the firm posted ($1.76) earnings per share. Travere Therapeutics's revenue was up 83.3% compared to the same quarter last year.

Institutional Inflows and Outflows

Several hedge funds and other institutional investors have recently bought and sold shares of TVTX. GF Fund Management CO. LTD. purchased a new position in shares of Travere Therapeutics during the 4th quarter valued at $31,000. Sterling Capital Management LLC lifted its holdings in Travere Therapeutics by 859.8% during the 4th quarter. Sterling Capital Management LLC now owns 2,361 shares of the company's stock worth $41,000 after purchasing an additional 2,115 shares in the last quarter. Caitong International Asset Management Co. Ltd purchased a new stake in Travere Therapeutics during the 1st quarter worth about $62,000. Gen Wealth Partners Inc purchased a new stake in Travere Therapeutics during the 4th quarter worth about $73,000. Finally, KBC Group NV purchased a new stake in Travere Therapeutics during the 1st quarter worth about $75,000.

Insider Buying and Selling

In other Travere Therapeutics news, insider Peter Heerma sold 1,771 shares of Travere Therapeutics stock in a transaction that occurred on Monday, May 5th. The stock was sold at an average price of $21.05, for a total value of $37,279.55. Following the completion of the sale, the insider directly owned 128,215 shares in the company, valued at approximately $2,698,925.75. The trade was a 1.36% decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which can be accessed through this hyperlink. Also, CFO Christopher R. Cline sold 1,784 shares of the business's stock in a transaction that occurred on Monday, May 5th. The shares were sold at an average price of $21.05, for a total value of $37,553.20. Following the sale, the chief financial officer owned 93,126 shares of the company's stock, valued at approximately $1,960,302.30. This represents a 1.88% decrease in their position. The disclosure for this sale can be found here. Insiders have sold a total of 23,342 shares of company stock valued at $485,753 over the last ninety days. 4.19% of the stock is owned by company insiders.

About Travere Therapeutics

Travere Therapeutics, Inc, a biopharmaceutical company, identifies, develops, and delivers therapies to people living with rare kidney and metabolic diseases. Its products include FILSPARI (sparsentan), a once-daily, oral medication designed to target two critical pathways in the disease progression of IgA Nephropathy (endothelin 1 and angiotensin-II); and Thiola and Thiola EC (tiopronin tablets) for the treatment of cystinuria, a rare genetic cystine transport disorder that causes high cystine levels in the urine and the formation of recurring kidney stones.